BioSpace News Archive

Santhera Pharmaceuticals announces the Company’s preliminary unaudited financial results for the year ended December 31, 2022, reports on progress with its lead drug candidate vamorolone for the treatment of DMD in the U.S. and Europe, and provides updates on its strategic and financing initiatives.As permitted by SIX Exchange Regulation, the Company will publish the full 2022 Annual Report by the end of May.

We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses.

Swedish Orphan Biovitrum AB announced its report for the first quarter of 2023

Exploratory feasibility studies of amorphOX® initiated in collaboration with two international biopharmaceutical and vaccine companies.

Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase 2a part of the combination study with fostrox and Lenvima® in HCC after completed dose escalation.

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the pre-specified interim analysis of the RENOTORCH study has been completed.

Ascentage Pharma announced that results from four clinical studies of the company’s key assets, including the first China-approved third-generation BCR-ABL tyrosine kinase inhibitor olverembatinib, Bcl-2 selective inhibitor lisaftoclax, MDM2-p53 inhibitor alrizomadlin, and FAK/ALK/ROS1 inhibitor, have been selected for presentations at the 2023 American Society of Clinical Oncology Annual Meeting.

Rockwell Medical, Inc. announced that its international partner, Drogsan Pharmaceuticals, submitted a Marketing Authorization application and GMP application for Triferic® AVNU to the Turkish Medicines and Medical Devices Agency, for which Drogsan received priority status and high priority status, respectively.

Eli Lilly and Company announced that tirzepatide achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.

Immunic, Inc. announced the appointment of Richard Rudick, M.D., a thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry, to its board of directors, effective April 26, 2023.